Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 81
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Lupus ; 23(2): 159-65, 2014 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-24300780

RESUMEN

OBJECTIVE: The objective of this paper is to evaluate whether the different International Society of Nephrology/Renal Pathology Society (ISN/RPS) classes of proliferative lupus nephritis (LN) have a distinct baseline presentation, short-term response to immunosuppression (IS) and long-term prognosis. METHODS: Ninety-eight patients with new onset (first renal biopsy) ISN/RPS proliferative LN (Class III: n=24; IV-S: n=23; IV-G: n=51) were diagnosed at our institution between 1995 and 2012 (Louvain Lupus Nephritis inception Cohort). Their baseline renal parameters, primary response to IS at one year, survival and long-term renal outcome (mean follow-up: 77 months) were compared. RESULTS: At baseline, serum creatinine and 24-hour proteinuria were higher in Class IV-G, as was activity index on renal biopsy in Class IV-S and IV-G compared to III. Upon treatment, renal parameters improved with the same kinetics and to the same extent in the three pathological classes. On repeat renal biopsies (n=43), activity indices dropped similarly. Poor outcomes (death, end-stage renal disease, renal impairment defined by an eGFR <60 ml/min/1.73 m(2)) did not statistically differ between groups, although there was a trend toward more renal impairment at follow-up in Class IV-G compared to IV-S and III. Finally, the presence of even mild chronic lesions on baseline biopsy was clearly predictive of late renal outcome. CONCLUSION: Subsetting proliferative LN into Class III, IV-S and IV-G provides less clinically discriminant prognostic information than baseline chronicity index.


Asunto(s)
Nefritis Lúpica/clasificación , Nefritis Lúpica/patología , Adulto , Bélgica , Estudios de Cohortes , Femenino , Estudios de Seguimiento , Humanos , Inmunosupresores/uso terapéutico , Riñón/patología , Nefritis Lúpica/tratamiento farmacológico , Masculino , Persona de Mediana Edad , Pronóstico , Estudios Prospectivos , Proteinuria/tratamiento farmacológico , Resultado del Tratamiento , Adulto Joven
2.
Clin Nephrol ; 76(5): 396-400, 2011 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-22000560

RESUMEN

We report the case of a 53-year-old woman treated for 8 years with Betaferon® (interferon-ß-1b), who developed mild renal failure with hypertension, proteinuria and glomerular hematuria. Kidney biopsy was consistent with thrombotic microangiopathy (TMA). Considering the strong evidence of interferon-α causing TMA and the numerous immunomodulatory activities shared by INF-α and -ß, we incriminated Betaferon as the etiological agent of TMA in our patient. To our knowledge, it is the first time such an association has been published.


Asunto(s)
Lesión Renal Aguda/inducido químicamente , Adyuvantes Inmunológicos/efectos adversos , Interferón beta/efectos adversos , Esclerosis Múltiple/tratamiento farmacológico , Microangiopatías Trombóticas/inducido químicamente , Femenino , Humanos , Interferon beta-1b , Persona de Mediana Edad
3.
J Exp Med ; 193(10): 1189-98, 2001 May 21.
Artículo en Inglés | MEDLINE | ID: mdl-11369790

RESUMEN

We show that cytotoxic T lymphocytes (CTLs) infiltrating a kidney tumor recognize a peptide encoded by an alternative open reading frame (ORF) of the macrophage colony-stimulating factor (M-CSF) gene. Remarkably, this alternative ORF, which is translated in many tumors concurrently with the major ORF, is also translated in some tissues that do not produce M-CSF, such as liver and kidney. Such a dissociation of the translation of two overlapping ORFs from the same gene is unexpected. The antigenic peptide encoded by the alternative ORF is presented by human histocompatibility leukocyte antigen (HLA)-B*3501 and has a length of 14 residues. Peptide elution indicated that tumor cells naturally present this 14 mer, which is the longest peptide known to be recognized by CTLs. Binding studies of peptide analogues suggest that it binds by its two extremities and bulges out of the HLA groove to compensate for its length.


Asunto(s)
Antígenos de Neoplasias/genética , Linfocitos Infiltrantes de Tumor/inmunología , Factor Estimulante de Colonias de Macrófagos/genética , Sistemas de Lectura Abierta , Péptidos/genética , Linfocitos T Citotóxicos/inmunología , Secuencia de Aminoácidos , Antígenos de Neoplasias/inmunología , Secuencia de Bases , Carcinoma de Células Renales/inmunología , Citotoxicidad Inmunológica , Antígeno HLA-B35 , Humanos , Neoplasias Renales , Factor Estimulante de Colonias de Macrófagos/inmunología , Datos de Secuencia Molecular , Péptidos/inmunología , Biosíntesis de Proteínas
4.
Ann Rheum Dis ; 69(1): 61-4, 2010 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-19155235

RESUMEN

OBJECTIVE: To update the follow-up of the Euro-Lupus Nephritis Trial (ELNT), a randomised prospective trial comparing low-dose (LD) and high-dose (HD) intravenous (IV) cyclophosphamide (CY) followed by azathioprine (AZA) as treatment for proliferative lupus nephritis. PATIENTS AND METHODS: Data for survival and kidney function were prospectively collected during a 10-year period for the 90 patients randomised in the ELNT, except in 6 lost to follow-up. RESULTS: Death, sustained doubling of serum creatinine and end-stage renal disease rates did not differ between the LD and HD group (5/44 (11%) vs 2/46 (4%), 6/44 (14%) vs 5/46 (11%) and 2/44 (5%) vs 4/46 (9%), respectively) nor did mean serum creatinine, 24 h proteinuria and damage score at last follow-up. Most patients in both groups were still treated with glucocorticoids, other immunosuppressant agents and blood pressure lowering drugs. After 10 years of follow-up, the positive predictive value for a good outcome of an early drop in proteinuria in response to initial immunosuppressive therapy was confirmed. CONCLUSION: The data confirm that a LD IVCY regimen followed by AZA-the "Euro-Lupus regimen"-achieves good clinical results in the very long term.


Asunto(s)
Ciclofosfamida/administración & dosificación , Inmunosupresores/administración & dosificación , Nefritis Lúpica/tratamiento farmacológico , Adolescente , Adulto , Azatioprina/uso terapéutico , Ciclofosfamida/uso terapéutico , Relación Dosis-Respuesta a Droga , Quimioterapia Combinada , Métodos Epidemiológicos , Femenino , Humanos , Inmunosupresores/uso terapéutico , Inyecciones Intravenosas , Pruebas de Función Renal , Nefritis Lúpica/fisiopatología , Masculino , Persona de Mediana Edad , Proteinuria/tratamiento farmacológico , Resultado del Tratamiento , Adulto Joven
5.
Clin Genet ; 77(3): 258-65, 2010 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-19817772

RESUMEN

The oral-facial-digital syndrome type I (OFD I) is characterized by multiple congenital malformations of the face, oral cavity and digits. A polycystic kidney disease (PKD) is found in about one-third of patients but long-term outcome and complications are not well described in the international literature. Renal findings have been retrospectively collected in a cohort of 34 females all carrying a pathogenic mutation in the OFD1 gene with ages ranging from 1 to 65 years. Twelve patients presented with PKD - 11/16 (69%) if only adults were considered -with a median age at diagnosis of 29 years [IQR (interquartile range) = (23.5-38)]. Among them, 10 also presented with renal impairment and 6 were grafted (median age = 38 years [IQR = (25-48)]. One grafted patient under immunosuppressive treatment died from a tumor originated from a native kidney. The probability to develop renal failure was estimated to be more than 50% after the age of 36 years. Besides, neither genotype-phenotype correlation nor clinical predictive association with renal failure could be evidenced. These data reveal an unsuspected high incidence rate of the renal impairment outcome in OFD I syndrome. A systematic ultrasound (US) and renal function follow-up is therefore highly recommended for all OFD I patients.


Asunto(s)
Envejecimiento , Síndromes Orofaciodigitales/complicaciones , Insuficiencia Renal/etiología , Adolescente , Adulto , Niño , Preescolar , Estudios de Cohortes , Femenino , Estudios de Asociación Genética , Humanos , Lactante , Riñón/patología , Persona de Mediana Edad , Síndromes Orofaciodigitales/genética , Síndromes Orofaciodigitales/patología , Síndromes Orofaciodigitales/fisiopatología , Proteínas/genética , Adulto Joven
6.
Clin Nephrol ; 71(5): 567-70, 2009 May.
Artículo en Inglés | MEDLINE | ID: mdl-19473619

RESUMEN

We describe an HIV1-positive patient under long-term tenofovir treatment who developed a severe, biopsy-proven, acute tubular necrosis with proximal tubule (PT) dysfunction, precipitated by the very recent start of diclofenac, a nonsteroidal antiinflammatory drug (NSAID). Recent studies show that NSAIDs not only alter glomerular filtration but also multidrug resistance protein (MRP) 4-mediated PT secretion of several substrates. Since the patient tolerated tenofovir well for several years prior to diclofenac use, our observation suggests that diclofenac interfered with tenofovir clearance, thereby favoring its nephrotoxicity. NSAIDs should be avoided in patients under tenofovir.


Asunto(s)
Lesión Renal Aguda/inducido químicamente , Adenina/análogos & derivados , Diclofenaco/efectos adversos , Síndrome de Fanconi/inducido químicamente , Anticuerpos Anti-VIH/inmunología , Seropositividad para VIH/tratamiento farmacológico , VIH-1/inmunología , Organofosfonatos/efectos adversos , Lesión Renal Aguda/patología , Adenina/efectos adversos , Adenina/uso terapéutico , Fármacos Anti-VIH/efectos adversos , Fármacos Anti-VIH/uso terapéutico , Antiinflamatorios no Esteroideos/efectos adversos , Antiinflamatorios no Esteroideos/uso terapéutico , Biopsia , Diagnóstico Diferencial , Diclofenaco/uso terapéutico , Sinergismo Farmacológico , Quimioterapia Combinada , Síndrome de Fanconi/patología , Femenino , Seropositividad para VIH/virología , Humanos , Túbulos Renales Proximales/efectos de los fármacos , Túbulos Renales Proximales/patología , Persona de Mediana Edad , Organofosfonatos/uso terapéutico , Tenofovir
7.
Clin Nephrol ; 70(2): 176-7, 2008 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-18793536

RESUMEN

We report moderate renal failure in a 50-year-old man with a history of recent colonoscopy after oral sodium phosphate purgative use. We initially missed the correct diagnosis, but renal biopsy revealed signs of acute phosphate nephropathy. The patient had residual renal impairment at 8-month follow-up. Greater awareness of this complication is needed amongst health care professionals. The preventive strategies are discussed.


Asunto(s)
Catárticos/efectos adversos , Nefrocalcinosis/inducido químicamente , Biopsia , Colonoscopía , Creatinina/sangre , Humanos , Hiperfosfatemia/inducido químicamente , Enfermedad Iatrogénica , Masculino , Persona de Mediana Edad
8.
Clin Nephrol ; 69(4): 290-3, 2008 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-18397704

RESUMEN

We report a case of pauci-immune proliferative necrotizing and crescentic glomerulonephritis in a patient with systemic lupus erythematosus (SLE) who presented with a nephrotic syndrome, while SLE was clinically and serologically quiescent. Immunofluorescence and electron microscopy examination of the kidney biopsy failed to reveal any significant deposit of immunoglobulins as well as of complement C3 and C1q, excluding lupus nephritis as the determinant of crescentic glomerulonephritis. Anti-myeloperoxydase (MPO) as well as anti-proteinase 3 (PR3) antibodies were absent in the serum. An immunosuppressive regimen including corticosteroids and IV cyclophosphamide led to a dramatic decrease of proteinuria. We conclude that necrotizing glomerulonephritis unrelated to lupus nephritis may occur in a patient with quiescent SLE. An underlying dysfunction of cell-mediated immunity might explain the association of pauci-immune crescentic glomerulonephritis and SLE.


Asunto(s)
Ciclofosfamida/uso terapéutico , Glomerulonefritis/tratamiento farmacológico , Glomerulonefritis/etiología , Glucocorticoides/uso terapéutico , Inmunosupresores/uso terapéutico , Lupus Eritematoso Sistémico/complicaciones , Síndrome Nefrótico/etiología , Adulto , Ciclofosfamida/inmunología , Femenino , Glomerulonefritis/diagnóstico , Glomerulonefritis/inmunología , Humanos , Inmunidad Celular , Inmunosupresores/inmunología , Glomérulos Renales/patología , Lupus Eritematoso Sistémico/inmunología , Necrosis , Síndrome Nefrótico/diagnóstico , Síndrome Nefrótico/tratamiento farmacológico , Síndrome Nefrótico/inmunología , Proteinuria/etiología
9.
J Clin Invest ; 59(1): 69-81, 1977 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-187623

RESUMEN

125I-angiotensin II (AII) specifically bound to rat glomerular basement membrane (GBM). The kinetics of binding were similar to those obtained with the total glomeruli. The apparent dissociation constant was close to 50 pM with both preparations. The number of sites related to the amount of protein was two times greater with GBM than with total glomeruli. Since the amount of GBM protein extracted from a given amount of glomerular protein was about 10%, it was possible to estimate the share of the GBM binding sites for AII as representing 20% of the total number present in the entire glomerulus. Binding studies at equilibrium as a function of 125I-AII concentration and competitive binding experiments suggested either multiplicity of the binding sites or cooperativity in the binding reaction. Degradation of 125I-AII in the presence of GBM was slight and did not increase with time. The difference in the degrees of degradation of 125I-AII was too small to account for the observed difference in binding when the results obtained with GBM and isolated glomeruli preparations were compared. 125I-AII binding to GBM was increased after treatment of these membranes with collagenase, slightly diminished with neuraminidase, and almost completely abolished with trypsin suggesting the proteic nature of the receptor. 125I-AII binding to GBM was diminished after incubation of GBM with anti-GBM antibodies as a result of a decrease in the number of binding sites. 125I-AII binding was even more diminished in preparations of glomeruli isolated from rats passively immunized with anti-GBM antibodies when compared with glomeruli from control animals. This resulted from both smaller affinity for AII and decrease in the number of the binding sites. The present data provides evidence for specific binding sites for AII localized on GBM. This is noteworthy since receptors for polypeptide hormones are currently observed on the surface of cell membranes. These findings also suggest a new physiological role for AII which might involve modification of GBM permeability.


Asunto(s)
Angiotensina II/metabolismo , Membrana Basal/metabolismo , Glomérulos Renales/citología , Receptores de Angiotensina , Receptores de Superficie Celular , Animales , Anticuerpos , Creatinina/sangre , Femenino , Radioisótopos de Yodo , Proteinuria/metabolismo , Ratas
10.
Clin Nephrol ; 67(2): 105-8, 2007 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-17338430

RESUMEN

We report the case of a 42-year-old man who developed biopsy-confirmed acute interstitial nephritis (AIN) after cocaine sniffing. He required a few hemodialysis sessions but fully recovered within 3 weeks after cocaine withdrawal and a short course of corticosteroids. AIN should be recognized as a potential cause of acute renal failure in cocaine users, and a history of cocaine use should be carefully elicited in patients with unexplained AIN.


Asunto(s)
Trastornos Relacionados con Cocaína/complicaciones , Nefritis Intersticial/etiología , Enfermedad Aguda , Adulto , Biopsia , Diagnóstico Diferencial , Humanos , Masculino , Nefritis Intersticial/patología , Nefritis Intersticial/terapia
11.
Autoimmun Rev ; 5(3): 180-6, 2006 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-16483917

RESUMEN

The "Euro-Lupus Cohort" is composed by 1000 patients with systemic lupus erythematosus (SLE) that have been followed prospectively since 1991. These patients have been gathered by a European consortium--the "Euro-Lupus Project Group". This consortium was originated as part of the network promoted by the "European Working Party on SLE", a working group created in 1990 in order to promote research in Europe on the different problems related to this disease. The "Euro-Lupus Cohort" provides an updated information on the SLE morbidity and mortality characteristics in the present decade as well as defines several clinical and immunological prognostic factors.


Asunto(s)
Enfermedades Autoinmunes/diagnóstico , Enfermedades Autoinmunes/epidemiología , Lupus Eritematoso Sistémico/diagnóstico , Lupus Eritematoso Sistémico/epidemiología , Edad de Inicio , Anticuerpos Antinucleares/sangre , Enfermedades Autoinmunes/sangre , Enfermedades Autoinmunes/mortalidad , Estudios de Cohortes , Europa (Continente)/epidemiología , Femenino , Estudios de Seguimiento , Humanos , Lupus Eritematoso Sistémico/sangre , Lupus Eritematoso Sistémico/mortalidad , Masculino , Morbilidad , Pronóstico , Estudios Prospectivos , Tasa de Supervivencia
12.
Cancer Res ; 56(9): 2025-8, 1996 May 01.
Artículo en Inglés | MEDLINE | ID: mdl-8616845

RESUMEN

A unique type of rapidly progressive renal fibrosis, designated Chinese herbs nephropathy (CHN), has been described in young Belgian women who had followed a slimming regimen including recently introduced Chinese herbs (Stephania tetrandra and Magnolia officinalis). Aristolochic acid (AA), a known nephrotoxin and carcinogen, was suspected as its causal factor. To substantiate this hypothesis, renal tissue from five patients with CHN and six patients with other renal diseases was analyzed for the presence of AA-derived DNA adducts, a described biomarker of AA exposure associated with its carcinogenic and mutagenic activity. Using the 32P-postlabeling method, a major distinct DNA adduct spot was found in all five cases of CHN and identified by cochromatographic analyses with authentic markers as the deoxyadenosine adduct of AA-I [7-(deoxyadenosin-N6-yl)-aristolactam I], the major component of the plant extract AA. This DNA adduct was absent in the six control cases. The 7-(deoxyadenosin-N6-yl)-aristolactam I adduct levels in CHN ranged from 0.7 to 5.3/10(7) nucleotides. Our data demonstrate that AA is implicated in CHN. They suggest a mechanism for the urothelial atypia and cancers observed in this disease and raise the possibility that a DNA mutation is responsible for the kidney-destructive fibrotic process.


Asunto(s)
Ácidos Aristolóquicos , Aductos de ADN , Medicamentos Herbarios Chinos/efectos adversos , Enfermedades Renales/inducido químicamente , Riñón/efectos de los fármacos , Fenantrenos/efectos adversos , Adulto , Femenino , Humanos , Riñón/metabolismo , Enfermedades Renales/metabolismo , Fenantrenos/metabolismo
13.
Transplantation ; 58(11): 1179-86, 1994 Dec 15.
Artículo en Inglés | MEDLINE | ID: mdl-7992359

RESUMEN

The frequency and the risk factors for clinical recurrence of Henoch-Schönlein nephritis following renal transplantation (TP) remain largely unknown. We report on 14 transplants performed at our center in 10 patients, detail the evolution of 2 of them with clinical recurrence, and review 64 other transplants reported in the literature. In our series, all patients are currently alive. Seven grafts are well-functioning 22-295 (mean, 97) months after TP without any sign of clinical recurrence. Five grafts were lost from rejection. Clinical recurrence occurred in 2 patients who were on cyclosporine/azathioprine/prednisone therapy. Pooling our series with that of Hasegawa et al., the actuarial risk for renal recurrence and for graft loss due to recurrence was 35 and 11% at 5 years after TP, respectively. In our series, duration of original disease was 2 and 28 months in the 2 patients with recurrence versus 31-144 months in the others without recurrence. In the literature, this duration was < or = 36 months in all 7 patients with recurrence. Recurrence occurred despite a > 12-month delay between disappearance of purpura and TP in our 2 patients and in 3 of 6 previously reported recurrences. We conclude that Henoch-Schönlein purpura nephritis frequently recurs after TP. Recurrence (1) seems to be associated with a shorter duration of the original disease, (2) can occur despite a delay of more than 1 year (as commonly advised) between disappearance of purpura and TP, and (3) is not prevented by a triple immunosuppressive regimen that includes cyclosporine.


Asunto(s)
Vasculitis por IgA/etiología , Trasplante de Riñón/efectos adversos , Nefritis/etiología , Adolescente , Adulto , Niño , Preescolar , Femenino , Humanos , Vasculitis por IgA/complicaciones , Vasculitis por IgA/epidemiología , Vasculitis por IgA/cirugía , Masculino , Persona de Mediana Edad , Nefritis/complicaciones , Nefritis/epidemiología , Nefritis/cirugía , Factores de Riesgo , Análisis de Supervivencia
14.
Transplantation ; 52(5): 823-6, 1991 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-1949167

RESUMEN

Graft antiglomerular basement membrane nephritis in patients with Alport's syndrome (AS) is a unique complication related to the glomerular basement membrane (GBM) abnormality characteristic of the disease. Its prevalence and clinical significance however remain unknown. We used strict criteria of AS to select 30 patients (26 men, 4 women), aged 17 to 44 years (m: 27) in whom 35 grafts (30 first, 5 second) had been performed at our center between 1968 and 1988. Patient and graft survival were, respectively, 96 and 75% at 5 years, 77 and 42% at 10 years. Graft survival and function, as well as the incidence of rejection episodes in the AS group were not different from those of a control group without AS, matched for age, sex, graft origin, and immunosuppressive regimen. Fifteen grafts were examined by immunofluorescence at least 3 months after TP: linear IgG deposits along GBM were present in 5 cases in the absence of signs of crescentic glomerulonephritis. Circulating anti-GBM antibodies detected in one of these cases 8 months post-TP had disappeared 24 months later. The presence of linear IgG did not seem to influence graft survival and function. We conclude: (1) the overall outcome of TP in AS patients does not differ from a control group without AS; (2) appearance of linear glomerular IgG is frequent but is not necessarily associated with a poor graft outcome; (3) the course of de novo graft anti-GBM disease may be benign; and (4) the aggressivity of the disease could be determined by the degree of immunosuppression and/or by the specificity of the anti-GBM antibodies.


Asunto(s)
Trasplante de Riñón , Nefritis Hereditaria/cirugía , Adulto , Anciano , Creatinina/sangre , Femenino , Técnica del Anticuerpo Fluorescente , Rechazo de Injerto , Supervivencia de Injerto , Hematuria/etiología , Humanos , Inmunoglobulina G/biosíntesis , Glomérulos Renales/inmunología , Trasplante de Riñón/efectos adversos , Trasplante de Riñón/mortalidad , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Resultado del Tratamiento
15.
Transplantation ; 49(3): 515-8, 1990 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-2316013

RESUMEN

The fate of tuberous sclerosis (TS) patients after renal transplantation (RT) for end-stage renal failure remains to be defined. We report three patients with a posttransplantation follow-up averaging 54 months and review 6 previously published cases. Three women, aged 27-46 years, received a cadaver kidney 26-67 months after starting dialysis. None had mental retardation, 2 had suffered from seizures during infancy and 2 had intracranial calcification; neurological involvement was equally mild in the 6 reported patients. Currently, 16-84 months after RT, our 3 patients are fully rehabilitated with a well-functioning graft (serum creatinine 1.2-1.7 mg/dl). Results of RT are also satisfactory in the 4 other reported cases for whom a follow-up is available, except for 1 death unrelated to the initial disease. Neurologic disorders did not progress. Renal cell carcinoma was discovered in one removed kidney, and cells suggestive of malignant transformation in another case. No metastases were discovered up to 4 years later. No neoplastic transformation was observed up to 7 years after RT in the 3 patients who retained their native kidneys. TS patients with end-stage renal failure are good candidates for RT. The probably small risk of neoplastic transformation of native kidneys warrants a close monitoring by CT scan of the few patients who have not undergone bilateral nephrectomy.


Asunto(s)
Trasplante de Riñón , Esclerosis Tuberosa/cirugía , Adulto , Cadáver , Femenino , Estudios de Seguimiento , Humanos , Persona de Mediana Edad , Pronóstico , Esclerosis Tuberosa/patología
16.
Am J Kidney Dis ; 33(2): 383-8, 1999 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-10023655

RESUMEN

Aquaporin-1 (AQP1) has been claimed to be the molecular counterpart of the transcellular pathway for free-water movement across the peritoneum during peritoneal dialysis. We report the case of a 67-year-old man, on peritoneal dialysis for 11 years, in whom ultrafiltration failure due to an abolition of the transcellular water transfer (documented by a loss of sodium sieving) was associated with an apparently normal expression of AQP1. We suggest that an alteration of AQP1 structure, rather than of its expression, accounts for this observation.


Asunto(s)
Acuaporinas/metabolismo , Fallo Renal Crónico/metabolismo , Diálisis Peritoneal , Peritoneo/metabolismo , Agua/metabolismo , Anciano , Acuaporina 1 , Transporte Biológico Activo , Antígenos de Grupos Sanguíneos , Western Blotting , Regulación de la Expresión Génica , Humanos , Inmunohistoquímica , Fallo Renal Crónico/patología , Fallo Renal Crónico/terapia , Masculino , Microscopía , Peritoneo/patología , Permeabilidad , Insuficiencia del Tratamiento , Ultrafiltración
17.
Am J Kidney Dis ; 36(6): 1271-5, 2000 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-11096053

RESUMEN

We report on four patients, from three different families, with Senior-Loken syndrome (SLS). They were unusual in that they reached end-stage renal failure (ESRF) only during the fifth or sixth decade. SLS is an autosomal-recessive disorder defined by the association of nephronophthisis and retinal dystrophy. Affected individuals invariably progress to ESRF, usually before the age of 20 years. The diagnosis was based on typical clinical presentation and characteristic renal histology, that is, a picture of chronic interstitial nephritis with pronounced thickening and multilayering of tubular basement membranes. Deterioration of renal function was slow, leading to ESRF between the ages of 42 and 56 years. Retinal dystrophy, already symptomatic during childhood in two patients, led to severe visual impairment in all. In contrast with four cases of SLS recently reported in very young patients, the NPH1 gene (the main gene responsible for nephronophthisis) was not deleted in our two tested patients. We conclude that SLS should be considered in adults who suffer from both chronic interstitial nephropathy and retinal degeneration. Whether the SLS is a variant of nephronophthisis and whether early- and late-onset renal failure in SLS is accounted for by genetic or allelic heterogeneity remain to be determined.


Asunto(s)
Fallo Renal Crónico/diagnóstico , Enfermedades Renales Poliquísticas/diagnóstico , Degeneración Retiniana/diagnóstico , Adulto , Edad de Inicio , Comorbilidad , Femenino , Humanos , Fallo Renal Crónico/etiología , Masculino , Persona de Mediana Edad , Enfermedades Renales Poliquísticas/epidemiología , Enfermedades Renales Poliquísticas/genética , Degeneración Retiniana/epidemiología , Degeneración Retiniana/genética , Síndrome
18.
Am J Kidney Dis ; 34(1): 166-9, 1999 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-10401033

RESUMEN

The fate of preexisting benign monoclonal gammopathy after organ transplantation is largely unknown. We report the case of a 47-year-old male kidney graft recipient with a pretransplantation IgG kappa monoclonal gammopathy who developed, 10 years after transplantation, de novo augloid light chain (AL) amyloidosis involving skin and kidney graft. The potential role of heavy immunosuppressive treatment in the development of this complication is discussed. The possible occurrence of AL amyloidosis should be kept in mind when a patient with benign monoclonal gammopathy is evaluated for organ transplantation, as well as when a transplanted patient with pre-existing monoclonal gammopathy develops new onset of proteinuria.


Asunto(s)
Amiloidosis/inmunología , Inmunoglobulina G/inmunología , Cadenas kappa de Inmunoglobulina/inmunología , Trasplante de Riñón , Gammopatía Monoclonal de Relevancia Indeterminada/inmunología , Amiloidosis/patología , Humanos , Inmunosupresores/efectos adversos , Riñón/patología , Trasplante de Riñón/inmunología , Trasplante de Riñón/patología , Masculino , Persona de Mediana Edad , Piel/patología , Factores de Tiempo
19.
Am J Kidney Dis ; 33(6): 1011-7, 1999 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-10352187

RESUMEN

Rapidly progressive renal fibrosis after a slimming regimen including Chinese herbs containing aristolochic acid (AA) has been identified as Chinese-herb nephropathy (CHN). We reported urothelial atypia in three patients with CHN, with the subsequent development in one patient of overt transitional cell carcinoma (TCC). Therefore, it was decided to remove the native kidneys, as well as the ureters, in all patients with CHN. Nineteen kidneys and ureters removed during and/or after renal transplantation from 10 patients were studied to assess critically urothelial lesions and to characterize the cellular expression of p53, a tumor-suppressor gene overexpressed in several types of malignancies. Multifocal high-grade flat TCC in situ (carcinoma in situ; CiS) was observed, mainly in the upper urinary tract, in four patients, a prevalence of 40%. In one of those patients, a superficially invasive flat TCC of the right upper ureter, as well as two additional foci of noninvasive papillary TCC, were found in the right pelvis and left lower ureter, respectively. This patient also presented recurrent noninvasive papillary TCC of the bladder. Furthermore, in all cases, multifocal, overall moderate atypia was found in the medullary collecting ducts, pelvis, and ureter. All CiS and papillary TCC, as well as urothelial atypia, overexpressed p53. These results show that the intake of Chinese herbs containing AA has a dramatic carcinogenic effect. Carcinogenesis is associated with the overexpression of p53, which suggests a role for a p53 gene mutation. The relationship of this mutation with the reported presence of AA DNA adducts in the kidney remains to be explored.


Asunto(s)
Ácidos Aristolóquicos , Carcinógenos , Carcinoma in Situ/inducido químicamente , Carcinoma de Células Transicionales/inducido químicamente , Medicamentos Herbarios Chinos/efectos adversos , Enfermedades Renales/inducido químicamente , Neoplasias Renales/inducido químicamente , Fenantrenos/efectos adversos , Adulto , Femenino , Humanos , Riñón/patología , Enfermedades Renales/genética , Enfermedades Renales/patología , Persona de Mediana Edad , Proteína p53 Supresora de Tumor/análisis , Uréter/patología , Neoplasias Ureterales/inducido químicamente
20.
Am J Kidney Dis ; 38(5): E26, 2001 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-11684578

RESUMEN

The causal role of aristolochic acid (AA) in the so-called Chinese herbs nephropathy (CHN) has been conclusively demonstrated only in the Belgian epidemic. We report a biopsy-proven hypocellular interstitial fibrosing nephropathy in a Chinese patient who had ingested a Chinese herbal preparation bought in Shanghai. The identification of AA in the preparation and of AA-DNA adducts in the kidney tissue unequivocally demonstrates, for the first time, the causal role of AA outside the Belgian epidemic. Because the ingested preparation is very popular in China as an over-the-counter product, our observation raises the possibility that many such cases due to AA might be currently unrecognized in China. AA should be banned from herbal preparations worldwide. All cases of the so-called CHN, in which the causal role of AA has been thoroughly documented, should be further identified as aristolochic acid nephropathy (AAN). The term phytotherapy-associated interstitial nephritis (PAIN) might refer to the other cases associated with phytotherapy without identification, as yet, of the causal agent.


Asunto(s)
Ácidos Aristolóquicos , Fenantrenos/efectos adversos , Insuficiencia Renal/inducido químicamente , Aductos de ADN , Medicamentos Herbarios Chinos/efectos adversos , Femenino , Humanos , Riñón/efectos de los fármacos , Riñón/patología , Riñón/fisiopatología , Persona de Mediana Edad , Terminología como Asunto
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA